Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Curanex Pharmaceuticals Inc (CURX : NSDQ)

• Company Description    Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases. Its lead candidate includes Phyto-N. Curanex Pharmaceuticals Inc. is headquartered in Jericho, New York. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $5.05 Daily Weekly Monthly 20 Day Moving Average: 22,685 shares Shares Outstanding: 1.57 (millions) Market Capitalization: $7.92 (millions) Beta: 52 Week High: $183.59 52 Week Low: $3.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 30.56% 31.14% 12 Week -25.18% -26.78% Year To Date -23.62% -32.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 JERICHO PLAZA SUITE 101B - JERICHO,NY 11753 USA ph: 718-673-6078 fax: - None http://www.curanexpharma.com

• General Corporate Information    Officers Jun Liu - Chief Executive Officer; President and Director Liqin Xie - Chief Operating Officer Wanjun Zhang - Chief Financial Officer and Treasurer Yong Yan - Director Xiaohui Hao - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 23126K304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 1.57 Most Recent Split Date: 8.00 (0.05:1) Beta: Market Capitalization: $7.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.50 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 72.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -82.07 03/31/26 - -85.41 12/31/25 - -65.46 ROA 06/30/26 - -79.65 03/31/26 - -82.11 12/31/25 - -62.95 Current Ratio 06/30/26 - 45.95 03/31/26 - 62.87 12/31/25 - 81.94 Quick Ratio 06/30/26 - 45.95 03/31/26 - 62.88 12/31/25 - 81.94 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 3.38 03/31/26 - 5.70 12/31/25 - 7.92 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©